Auvelity Composition
Auvelity contains two active ingredients: dextromethorphan hydrobromide 45 mg (immediate-release) and bupropion hydrochloride 105 mg (extended-release) in each tablet. 1
Active Ingredients
- Dextromethorphan hydrobromide: 45 mg per tablet (equivalent to 32.98 mg dextromethorphan base) in an immediate-release formulation
- Bupropion hydrochloride: 105 mg per tablet (equivalent to 91.14 mg bupropion base) in an extended-release formulation
The combination is designed so that bupropion inhibits CYP2D6, which prevents the rapid metabolism of dextromethorphan, thereby increasing its bioavailability and therapeutic levels 1, 2.
Inactive Ingredients
Each tablet contains the following inactive excipients 1:
- L-cysteine hydrochloride monohydrate
- Carbomer homopolymer
- Microcrystalline cellulose
- Colloidal silicon dioxide
- Crospovidone
- Stearic acid
- Magnesium stearate
- Glyceryl monocaprylocaprate
- Polyvinyl alcohol
- Sodium lauryl sulfate
- Talc
- Titanium dioxide
- Red iron oxide
- Yellow iron oxide
Mechanism of Action
Dextromethorphan acts as an uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist, while bupropion functions as a norepinephrine/dopamine reuptake inhibitor and CYP2D6 inhibitor 1, 2. The bupropion component serves a dual purpose: it provides antidepressant effects through noradrenergic and dopaminergic mechanisms, and it competitively inhibits the metabolism of dextromethorphan, preventing its conversion to dextrorphan (which has mu-opioid agonist properties) 3.
Formulation Details
The medication is formulated as round bilayer tablets for oral administration, with the dextromethorphan in an immediate-release layer and bupropion in an extended-release layer 1. This specific formulation design allows for the pharmacokinetic synergy between the two components, where bupropion maintains consistent dextromethorphan levels throughout the dosing interval 3.